tetano
Editor, Senior Moderator
Sci Rep
. 2021 Dec 9;11(1):23713.
doi: 10.1038/s41598-021-03273-0.
The potential of COVID-19 patients' sera to cause antibody-dependent enhancement of infection and IL-6 production
Jun Shimizu[SUP] 1 [/SUP], Tadahiro Sasaki[SUP] 2 [/SUP], Atsushi Yamanaka[SUP] 1 3 [/SUP], Yoko Ichihara[SUP] 1 [/SUP], Ritsuko Koketsu[SUP] 2 [/SUP], Yoshihiro Samune[SUP] 2 [/SUP], Pedro Cruz[SUP] 1 [/SUP], Kei Sato[SUP] 1 [/SUP], Naomi Tanga[SUP] 1 [/SUP], Yuka Yoshimura[SUP] 1 [/SUP], Ami Murakami[SUP] 1 [/SUP], Misuzu Yamada[SUP] 1 [/SUP], Kiyoe Itoi[SUP] 1 [/SUP], Emi E Nakayama[SUP] 2 [/SUP], Kazuo Miyazaki[SUP] 4 [/SUP], Tatsuo Shioda[SUP] 5 6 [/SUP]
Affiliations
Abstract
Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many vaccine trials have been initiated. An important goal of vaccination is the development of neutralizing antibody (Ab) against SARS-CoV-2. However, the possible induction of antibody-dependent enhancement (ADE) of infection, which is known for other coronaviruses and dengue virus infections, is a particular concern in vaccine development. Here, we demonstrated that human iPS cell-derived, immortalized, and ACE2- and TMPRSS2-expressing myeloid cell lines are useful as host cells for SARS-CoV-2 infection. The established cell lines were cloned and screened based on their function in terms of susceptibility to SARS-CoV-2-infection or IL-6 productivity. Using the resulting K-ML2 (AT) clone 35 for SARS-CoV-2-infection or its subclone 35-40 for IL-6 productivity, it was possible to evaluate the potential of sera from severe COVID-19 patients to cause ADE and to stimulate IL-6 production upon infection with SARS-CoV-2.
. 2021 Dec 9;11(1):23713.
doi: 10.1038/s41598-021-03273-0.
The potential of COVID-19 patients' sera to cause antibody-dependent enhancement of infection and IL-6 production
Jun Shimizu[SUP] 1 [/SUP], Tadahiro Sasaki[SUP] 2 [/SUP], Atsushi Yamanaka[SUP] 1 3 [/SUP], Yoko Ichihara[SUP] 1 [/SUP], Ritsuko Koketsu[SUP] 2 [/SUP], Yoshihiro Samune[SUP] 2 [/SUP], Pedro Cruz[SUP] 1 [/SUP], Kei Sato[SUP] 1 [/SUP], Naomi Tanga[SUP] 1 [/SUP], Yuka Yoshimura[SUP] 1 [/SUP], Ami Murakami[SUP] 1 [/SUP], Misuzu Yamada[SUP] 1 [/SUP], Kiyoe Itoi[SUP] 1 [/SUP], Emi E Nakayama[SUP] 2 [/SUP], Kazuo Miyazaki[SUP] 4 [/SUP], Tatsuo Shioda[SUP] 5 6 [/SUP]
Affiliations
- PMID: 34887501
- DOI: 10.1038/s41598-021-03273-0
Abstract
Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many vaccine trials have been initiated. An important goal of vaccination is the development of neutralizing antibody (Ab) against SARS-CoV-2. However, the possible induction of antibody-dependent enhancement (ADE) of infection, which is known for other coronaviruses and dengue virus infections, is a particular concern in vaccine development. Here, we demonstrated that human iPS cell-derived, immortalized, and ACE2- and TMPRSS2-expressing myeloid cell lines are useful as host cells for SARS-CoV-2 infection. The established cell lines were cloned and screened based on their function in terms of susceptibility to SARS-CoV-2-infection or IL-6 productivity. Using the resulting K-ML2 (AT) clone 35 for SARS-CoV-2-infection or its subclone 35-40 for IL-6 productivity, it was possible to evaluate the potential of sera from severe COVID-19 patients to cause ADE and to stimulate IL-6 production upon infection with SARS-CoV-2.